Saturday: It’s Official…FDA Not Recommending Recall of Metformin

As a person with prediabetes who takes metformin, I am excited to share that the FDA recommends no recall on metformin. This is a follow up from Tuesday’s Daily Piece regarding the testing of metformin for NDMA. Please share this good news.

https://www.medscape.com/viewarticle/924866

Image result for metformin
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#metformin #no #recall #FDA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Tuesday’s Daily Piece: Good News Regarding NDMA in Metformin

If you recall in 2019, several generic medications were pulled from the market due to having unacceptable levels of N-Nitrosodimethylamine (NDMA) impurity as NDMA increases risk of cancer. Concerns regarding the level of NDMA in generic metformin surfaced in late 2019. Good news came out earlier this week that the FDA found no tested samples of generic metformin contained unacceptable levels of NDMA important. Please click below to found additional details regarding the tested samples of metformin.

https://www.raps.org/news-and-articles/news-articles/2020/2/ndma-in-metformin-fda-finds-low-levels-in-only-2

Image result for metformin
Image result for fda
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#metformin #NDMA #FDA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Thursday’s Daily Piece: Real World Case of “If Sounds Too Good to Be True, Then It Probably Is”

CVS Health announced a new program, RxZERO, which sounds amazing. It promises to eliminate out of pocket expenses for diabetes medications. Wow!!! Oh exciting until you read closely that it requires employees with diabetes to use only approved generic diabetes medications – no branded medications. So this “amazing” program does not eliminate copays for SGLT-2 inhibitors, GLP-1 agonists, most DPP-IV inhibitors, branded insulin.

https://www.benefitnews.com/news/cvs-health-eliminates-out-of-pocket-costs-for-diabetes-medications

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#RxZERO #disappointed #generic #drugs

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Tuesday’s Daily Piece: New 3-in-1 Medication Combination Available

I don’t know about you but I like the idea of 3 meds in 1 pill. Well we now have a new 3 in 1 diabetes combination medication on the market. Trijardy XR contains empagliflozin (Jardiance) (SGLT2 inhibitor with additional indication to reduce risk of cardiovascular (heart related) death in adults with type 2 diabetes and established cardiovascular disease), linagliptin (Tradjenta) (DPP-IV inhibitor) and metformin XR (backbone of treatment for type 2 diabetes).

https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-only-triple-combination-tablet-jardiancer-adults

Image result for trijardy xr
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#3-in-1 #combination #TrijardyXR

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Saturday’s Daily Piece: Diabetes Educators are Now Diabetes Care and Education Specialists

I am thrilled to share the exciting new name of diabetes care and education specialists for the specialty formerly known as diabetes educators. This new title for the specialty more accurately captures the role of the specialty. Certified diabetes educators are now certified diabetes care and education specialists. As a diabetes care and education specialists myself, I do more than simply educate. American Association of Diabetes Educators (AADE) is now the Association of Diabetes Care and Education Specialist (ADCES). Having served on the Board of Directors of AADE during the process of changing name of specialty and association, I confidentiality say that the research backs the name change as well as input from key stakeholders. For more information on the timely and essential name change, please click below.

https://www.diabeteseducator.org/practice/new-name-title

Image result for adces
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#ACDES #new #name #specialty

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Tuesday’s Daily Piece: Gout Reduction Benefit with SGLT-2 Inhibitors

In a recent study published in Annals of Internal Medicine, sodium glucose cotransporter-2 (SGLT2) inhibitors were found to have a reduced risk for gout as compared to glucagon like peptide 1 (GLP-1) agonist. In this study patient taking SGLT2 inhibitor had 36% reduced risk of developing gout. The study design, population-based cohort study, is not the most robust study design as well as gout risk factors were not accessed in the study. While this is promising, more studies are needed.

https://annals.org/aim/article-abstract/2758844/assessing-risk-gout-sodium-glucose-cotransporter-2-inhibitors-patients-type

Image result for gout
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#gout #reduction #SGLT-2 inhibitors

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Saturday’s Daily Piece: Ozempic and Cardiovascular Benefit

The benefits or harms of diabetes medications on cardiovascular health matters in a major way. In recent years, medications particularly select GLP-1 agonists and SGLT-2 inhibitors have shown major cardiovascular benefits. Ozempic, a GLP-1 agonist, now has a FDA indication for reduction of major adverse cardiovascular events (i.e. heart attack, stroke) in adults with type 2 diabetes and known (diagnosed) heart disease. Please click more for details.

https://www.prnewswire.com/news-releases/fda-approves-ozempic-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-and-known-heart-disease-updates-rybelsus-label-300988672.html

Image result for ozempic heart indication
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#heart #reduction #Ozempic #indication

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Tuesday’s Daily Piece: New Lower-Priced Insulin

We all know that cost of insulin is HIGH!!! Several of the insulin manufacturers are implementing various cost lowering and/or savings programs that aim to address the pricing concerns. Eli Lilly in 2019 created lower-priced version of meal time insulin, Humalog. Now in 2020, they will now be introducing two additional lower-priced versions of their insulins, Humalog Junior KwikPen and Humalog Mix 75/25. The list price will be $265.20 for a pack of five KwikPens. While this is certainly a move in the right direction, I am still deeply concerned about the cost of insulin.

https://www.reuters.com/article/us-lilly-insulin/eli-lilly-to-launch-half-priced-versions-of-two-more-insulin-products-idUSKBN1ZD1JN

Image result for eli lilly half price insulin
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#lower #priced #insulin #diabetes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Saturday’s Daily Piece: Not All Clicks Are Equal

Recently, a person with type 2 diabetes shared with her health care provider that she counted the number of clicks to deliver her Victoza dose in a similar fashion as her Lantus dose. For insulin pens, each click of the pen indicates increase of 1 – 2 units of insulin. She understood each click after the first click of Victoza pen to increase her dose by 0.6 mg. However, this is not the case. Education in how to properly use each pen device is key as they are not equal in number of clicks to deliver correct dose.

Image result for victoza pen
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#counting #clicks #pen #device #diabetes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Tuesday’s Daily Piece: Additional Rapid Acting Insulin Option for Children with Diabetes

Insulin aspart with niacinamide (Fiasp) is now approved for use in pediatric (children) with diabetes. Niacinamide allows for faster absorption of insulin aspart. Fiasp was approved in 2017, and expanded to use in insulin pumps in 2019. Excited to have another rapid acting insulin analog options for children. To learn more, please click below.

https://www.medscape.com/viewarticle/923435

Image result for fiasp
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#children #diabetes #insulin #Fiasp

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.